SEC Form 4 · accession 0001144204-17-049455
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jarrod Longcor
Officer — Chief Business Officer
Period of report
Sep 18, 2017
Accepted (ET)
Sep 25, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $1.83 | Sep 18, 2017 | A | 25,000 | A | — | Sep 18, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Option vests in equal quarterly increments over a period of three years from the date of grant.